Chondroitin Sulfate Glycosaminoglycan Matrices Promote Neural Stem Cell Maintenance and Neuroprotection Post-Traumatic Brain Injury.
Autor: | Betancur MI; Regenerative Bioscience Center, The University of Georgia, 425 River Road, ADS Complex, Athens, Georgia 30602, United States., Mason HD; Regenerative Bioscience Center, The University of Georgia, 425 River Road, ADS Complex, Athens, Georgia 30602, United States., Alvarado-Velez M; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Drive, Atlanta, Georgia 30332, United States., Holmes PV; Psychology Department, The University of Georgia, 125 Baldwin Street, Athens, Georgia 30602, United States., Bellamkonda RV; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Drive, Atlanta, Georgia 30332, United States., Karumbaiah L; Regenerative Bioscience Center, The University of Georgia, 425 River Road, ADS Complex, Athens, Georgia 30602, United States. |
---|---|
Jazyk: | angličtina |
Zdroj: | ACS biomaterials science & engineering [ACS Biomater Sci Eng] 2017 Mar 13; Vol. 3 (3), pp. 420-430. Date of Electronic Publication: 2017 Feb 13. |
DOI: | 10.1021/acsbiomaterials.6b00805 |
Abstrakt: | There are currently no effective treatments for moderate-to-severe traumatic brain injuries (TBIs). The paracrine functions of undifferentiated neural stem cells (NSCs) are believed to play a significant role in stimulating the repair and regeneration of injured brain tissue. We therefore hypothesized that fibroblast growth factor (FGF2) enriching chondroitin sulfate glycosaminoglycan (CS-GAG) matrices can maintain the undifferentiated state of neural stem cells (NSCs) and facilitate brain tissue repair subacutely post-TBI. Rats subjected to a controlled cortical impactor (CCI) induced TBI were intraparenchymally injected with CS-GAG matrices alone or with CS-GAG matrices containing PKH26GL labeled allogeneic NSCs. Nissl staining of brain tissue 4 weeks post-TBI demonstrated the significantly enhanced ( p < 0.05) tissue protection in CS-GAG treated animals when compared to TBI only control, and NSC only treated animals. CS-GAG-NSC treated animals demonstrated significantly enhanced ( p < 0.05) FGF2 retention, and maintenance of PKH26GL labeled NSCs as indicated by enhanced Sox1+ and Ki67+ cell presence over other differentiated cell types. Lastly, all treatment groups and sham controls exhibited a significantly ( p < 0.05) attenuated GFAP+ reactive astrocyte presence in the lesion site when compared to TBI only controls. Competing Interests: Notes The authors declare no competing financial interest. |
Databáze: | MEDLINE |
Externí odkaz: |